Relationship between clinical improvement and functional gains with clozapine in schizophrenia

European Neuropsychopharmacology

Volumn 24, Issue 10, 2014, Pages 1622-1629

  Lee, Jimmy ^a,b,c   Takeuchi, Hiroyoshi ^c,d   Fervaha, Gagan ^c,e   Bhaloo, Amaal ^c   Powell, Valerie ^c   Remington, Gary ^c,e,f  

^a INSTITUTE OF MENTAL HEALTH   (Singapore)

^b DUKE NUS MEDICAL SCHOOL   (Singapore)

^c CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^d KEIO UNIVERSITY   (Japan)

^e UNIVERSITY OF TORONTO   (Canada)

^f UNIVERSITY OF TORONTO   (Canada)

Author keywords

Antipsychotic; Psychosis; Psychosocial; Symptoms

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT;

ADULT; ARTICLE; BRIEF PSYCHIATRIC RATING SCALE; CLINICAL ARTICLE; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; MALE; NEGATIVE SYNDROME; SCHIZOPHRENIA; SOCIAL AND OCCUPATIONAL FUNCTIONING ASSESSMENT SCALE; SOCIAL PSYCHOLOGY; SYMPTOMATOLOGY; TREATMENT DURATION; TREATMENT OUTCOME; FOLLOW UP; MULTIVARIATE ANALYSIS; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; TIME FACTOR;

ADULT; ANTIPSYCHOTIC AGENTS; CLOZAPINE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MULTIVARIATE ANALYSIS; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TIME FACTORS; TREATMENT OUTCOME;

EID: 84907993041     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2014.08.003     Document Type: Article

References (48)

1. Andreasen N.C. Negative symptoms in schizophrenia. Definition and reliability. Arch. Gen. Psychiatry 1982, 39:784-788.
2. Ayesa-Arriola R., Rodriguez-Sanchez J.M., Perez-Iglesias R., Gonzalez-Blanch C., Pardo-Garcia G., Tabares-Seisdedos R., Vazquez-Barquero J.L., Crespo-Facorro B. The relevance of cognitive, clinical and premorbid variables in predicting functional outcome for individuals with first-episode psychosis: a 3 year longitudinal study. Psychiatry Res. 2013, 209:302-308.
3. Bondolfi G., Dufour H., Patris M., May J.P., Billeter U., Eap C.B., Baumann P. Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. The Risperidone Study Group. Am. J. Psychiatry 1998, 155:499-504.
4. Breier A., Schreiber J.L., Dyer J., Pickar D. National Institute of Mental Health longitudinal study of chronic schizophrenia. Prognosis and predictors of outcome. Arch. Gen. Psychiatry 1991, 48:239-246.
5. Buchanan R.W., Breier A., Kirkpatrick B., Ball P., Carpenter W.T. Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome. Am. J. Psychiatry 1998, 155:751-760.
6. Carter C.S. Understanding the glass ceiling for functional outcome in schizophrenia. Am. J. Psychiatry 2006, 163:356-358.
7. Ciapparelli A., Dell'Osso L., Bandettini di Poggio A., Carmassi C., Cecconi D., Fenzi M., Chiavacci M.C., Bottai M., Ramacciotti C.E., Cassano G.B. Clozapine in treatment-resistant patients with schizophrenia, schizoaffective disorder, or psychotic bipolar disorder: a naturalistic 48-month follow-up study. J. Clin. Psychiatry 2003, 64:451-458.
8. Citrome L. Unmet needs in the treatment of schizophrenia: new targets to help different symptom domains. J. Clin. Psychiatry 2014, 75(Suppl. 1):S21-S26.
9. Conley R.R., Kelly D.L. Management of treatment resistance in schizophrenia. Biol. Psychiatry 2001, 50:898-911.
10. Conley R.R., Richardson C., Kent D., Gournaris C., Zaremba S. Clozapine response varies in deficit versus non-deficit schizophrenic subjects. Biol. Psychiatry 1994, 35:746.
11. Davidson M., Galderisi S., Weiser M., Werbeloff N., Fleischhacker W.W., Keefe R.S., Boter H., Keet I.P., Prelipceanu D., Rybakowski J.K., Libiger J., Hummer M., Dollfus S., Lopez-Ibor J.J., Hranov L.G., Gaebel W., Peuskens J., Lindefors N., Riecher-Rossler A., Kahn R.S. Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST). Am. J. Psychiatry 2009, 166:675-682.
12. Eckert S.L., Diamond P.M., Miller A.L., Velligan D.I., Funderburg L.G., True J.E. A comparison of instrument sensitivity to negative symptom change. Psychiatry Res. 1996, 63:67-75.
13. Fervaha G., Agid O., McDonald K., Foussias G., Remington G. Daily activity patterns in remitted first-episode schizophrenia. Compr. Psychiatry 2014, 55:1182-1187.
14. Fervaha G., Foussias G., Agid O., Remington G. Impact of primary negative symptoms on functional outcomes in schizophrenia. Eur. Psychiatry 2014.
15. Fervaha G., Foussias G., Agid O., Remington G. Motivational and neurocognitive deficits are central to the prediction of longitudinal functional outcome in schizophrenia. Acta Psychiatr. Scand 2014.
16. Foussias G., Mann S., Zakzanis K.K., van Reekum R., Agid O., Remington G. Prediction of longitudinal functional outcomes in schizophrenia: the impact of baseline motivational deficits. Schizophr. Res. 2011, 132:24-27.
17. Foussias G., Remington G. Negative symptoms in schizophrenia: avolition and Occam[U+05F3]s razor. Schizophr. Bull. 2010, 36:359-369.
18. Friedman M. The use of ranks to avoid the assumption of normality implicit in the analysis of variance. J. Am. Stat. Assoc. 1937, 32:675-701.
19. Goldman H.H., Skodol A.E., Lave T.R. Revising axis V for DSM-IV: a review of measures of social functioning. Am. J. Psychiatry 1992, 149:1148-1156.
20. Goldman R.S., Axelrod B.N., Tandon R., Ribeiro S.C., Craig K., Berent S. Neuropsychological prediction of treatment efficacy and one-year outcome in schizophrenia. Psychopathology 1993, 26:122-126.
21. Green M.F. What are the functional consequences of neurocognitive deficits in schizophrenia?. Am. J. Psychiatry 1996, 153:321-330.
22. Guo X., Zhang Z., Zhai J., Fang M., Hu M., Wu R., Liu Z., Zhao J. Effects of antipsychotic medications on quality of life and psychosocial functioning in patients with early-stage schizophrenia: 1-year follow-up naturalistic study. Compr. Psychiatry 2012, 53:1006-1012. Early-stage Schizophrenia Outcome Study Investigators.
23. Heinrichs D.W., Hanlon T.E., Carpenter W.T. The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr. Bull. 1984, 10:388-398.
24. Johnstone E.C., Macmillan J.F., Frith C.D., Benn D.K., Crow T.J. Further investigation of the predictors of outcome following first schizophrenic episodes. Br. J. Psychiatry 1990, 157:182-189.
25. Jones P.B., Barnes T.R., Davies L., Dunn G., Lloyd H., Hayhurst K.P., Murray R.M., Markwick A., Lewis S.W. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch. Gen. Psychiatry 2006, 63:1079-1087.
26. Kane J., Honigfeld G., Singer J., Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch. Gen. Psychiatry 1988, 45:789-796.
27. Kane J.M., Marder S.R., Schooler N.R., Wirshing W.C., Umbricht D., Baker R.W., Wirshing D.A., Safferman A., Ganguli R., McMeniman M., Borenstein M. Clozapine and haloperidol in moderately refractory schizophrenia: a 6-month randomized and double-blind comparison. Arch. Gen. Psychiatry 2001, 58:965-972.
28. Kaneda Y., Jayathilak K., Meltzer H. Determinants of work outcome in neuroleptic-resistant schizophrenia and schizoaffective disorder: cognitive impairment and clozapine treatment. Psychiatry Res. 2010, 178:57-62.
29. Keefe R.S., Bilder R.M., Davis S.M., Harvey P.D., Palmer B.W., Gold J.M., Meltzer H.Y., Green M.F., Capuano G., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., Davis C.E., Hsiao J.K., Lieberman J.A. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch. Gen. Psychiatry 2007, 64:633-647. CATIE Investigators; Neurocognitive Working Group.
30. Keefe R.S., Goldberg T.E., Harvey P.D., Gold J.M., Poe M.P., Coughenour L. The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery. Schizophr. Res. 2004, 68:283-297.
31. Keefe R.S., Harvey P.D., Goldberg T.E., Gold J.M., Walker T.M., Kennel C., Hawkins K. Norms and standardization of the Brief Assessment of Cognition in Schizophrenia (BACS). Schizophr. Res. 2008, 102:108-115.
32. Leucht S., Cipriani A., Spineli L., Mavridis D., Orey D., Richter F., Samara M., Barbui C., Engel R.R., Geddes J.R., Kissling W., Stapf M.P., Lassig B., Salanti G., Davis J.M. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 2013, 382:951-962.
33. Meltzer H.Y., Alphs L., Green A.I., Altamura A.C., Anand R., Bertoldi A., Bourgeois M., Chouinard G., Islam M.Z., Kane J., Krishnan R., Lindenmayer J.P., Potkin S. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch. Gen. Psychiatry 2003, 60:82-91. International Suicide Prevention Trial Study Group.
34. Meltzer H.Y., Bastani B., Kwon K.Y., Ramirez L.F., Burnett S., Sharpe J. A prospective study of clozapine in treatment-resistant schizophrenic patients. I. Preliminary report. Psychopharmacology 1989, 99(Suppl.):S68-S72.
35. Meltzer H.Y., McGurk S.R. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr. Bull. 1999, 25:233-255.
36. Mohamed S., Rosenheck R., Swartz M., Stroup S., Lieberman J.A., Keefe R.S. Relationship of cognition and psychopathology to functional impairment in schizophrenia. Am. J. Psychiatry 2008, 165:978-987.
37. Norman R.M., Malla A.K., Cortese L., Cheng S., Diaz K., McIntosh E., McLean T.S., Rickwood A., Voruganti L.P. Symptoms and cognition as predictors of community functioning: a prospective analysis. Am. J. Psychiatry 1999, 156:400-405.
38. Oorschot M., Lataster T., Thewissen V., Lardinois M., van Os J., Delespaul P.A., Myin-Germeys I. Symptomatic remission in psychosis and real-life functioning. Br. J. Psychiatry 2012, 201:215-220.
39. Overall J.E., Gorham D.R. The Brief Psychiatric Rating Scale. Psychol. Rep. 1962, 10:799-812.
40. Perlick D.A., Rosenheck R.A., Kaczynski R., Bingham S., Collins J. Association of symptomatology and cognitive deficits to functional capacity in schizophrenia. Schizophr. Res. 2008, 99:192-199.
41. Rosenheck R., Cramer J., Xu W., Thomas J., Henderson W., Frisman L., Fye C., Charney D. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. N. Engl. J. Med. 1997, 337:809-815.
42. Shafer A. Meta-analysis of the brief psychiatric rating scale factor structure. Psychol. Assess. 2005, 17:324-335.
43. Smith G.N., Ehmann T.S., Flynn S.W., MacEwan G.W., Tee K., Kopala L.C., Thornton A.E., Schenk C.H., Honer W.G. The assessment of symptom severity and functional impairment with DSM-IV axis V. Psychiatr. Serv. 2011, 62:411-417.
44. Suzuki T., Remington G., Mulsant B.H., Uchida H., Rajji T.K., Graff-Guerrero A., Mimura M., Mamo D.C. Defining treatment-resistant schizophrenia and response to antipsychotics: a review and recommendation. Psychiatry Res. 2012, 197:1-6.
45. Swartz M.S., Perkins D.O., Stroup T.S., Davis S.M., Capuano G., Rosenheck R.A., Reimherr F., McGee M.F., Keefe R.S., McEvoy J.P., Hsiao J.K., Lieberman J.A. Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. Am. J. Psychiatry 2007, 164:428-436. CATIE Investigators.
46. Tandon R., Ribeiro S.C., DeQuardo J.R., Goldman R.S., Goodson J., Greden J.F. Covariance of positive and negative symptoms during neuroleptic treatment in schizophrenia: a replication. Biol. Psychiatry 1993, 34:495-497.
47. van Os J., Kapur S. Schizophrenia. Lancet 2009, 374:635-645.
48. Whiteford H.A., Degenhardt L., Rehm J., Baxter A.J., Ferrari A.J., Erskine H.E., Charlson F.J., Norman R.E., Flaxman A.D., Johns N., Burstein R., Murray C.J., Vos T. Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. Lancet 2013, 382:1575-1586.